[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"R3 Stem Cell\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100543870","phase-1-safety-and-feasibility-of-umbilical-cord-whartons-jelly-allograft-injections-for-lumbar-pain-100543870",false,"NCT06361485","Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain","Inclusion Criteria:\n\n• Patient must\n\n* Be over age 20.\n* Suffering from chronic lumbar pain\n* Body Mass Index (BMI) \\\u003C50 Kilograms\u002Fm2.\n* Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS).\n* Female participants must be abstinent, surgically sterilized or postmenopausal.\n* Premenopausal females must be on contraceptive measures and do not anticipate pregnancy during the duration of the study.\n* Be willing and capable of giving written informed consent to participate in English.\n* Be willing and capable of complying with study-related requirements, procedures and visits.\n\nExclusion Criteria:\n\n• Patient must not\n\n* Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date.\n* Use anticoagulants have a substance abuse history, and fail to agree not to take any lumbar symptom modifying drugs during the course of the study without discussing and reporting the use to the site Clinical investigator and study team.\n* Known allergy to penicillin, sulfa or amphotericin medications.\n* Have had any lumbar injections (at all) of any drug in lumbar spine in the past 6 months.\n* Have had surgery on the lumbar spine within the past 6 months.\n* Had a traumatic injury to the lumbar spine with the past 3 months.\n* Planned elective surgery during the course of the study.\n* A history of organ or hematologic transplantation, rheumatoid arthritis, or other autoimmune disorders.\n* Be on immunosuppressive medications.\n* Have a diagnosis of carcinoma with the past 5 years.\n* Have a lumbar infection or have used antibiotics for lumbar infection within the past 3 months.\n* Have participated in any other clinical study or treatment (not just for the lumbar spine, but for any reason) with any investigational product within the past 30 days prior to inclusion of study.\n* Female participants who are breast feeding or are pregnant or desire to become pregnant during the course of the study.\n* Contraindications to radiographic or MRI imaging.\n* Serious neurological, psychological or psychiatric disorders.\n* Injury or disability claims under current litigation or pending or approved workers compensation claims.","ALL","20 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.",[25],"Low Back Pain",[27,28,29,30,31,32,33,34,35],"lumbago","low back pain","lumbar spondylosis","lumbar arthritis","facet syndrome","umbilical","umbilical cord allograft","stem cell","exosome","RECRUITING","2024-04-09",{"date":39,"type":40},"2024-04-11","ACTUAL",{"date":42,"type":40},"2024-03-25",{"date":44,"type":19},"2028-04-01",{"name":46,"class":47},"R3 Stem Cell","INDUSTRY",4,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":15,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":20,"phases":60,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100315776","evaluation-of-outcomes-with-umbilical-cord-allograft-for-musculoskeletal-conditions-musculoskeletal-conditions-100315776","NCT03390920","Evaluation of Outcomes With Umbilical Cord Allograft for Musculoskeletal Conditions Musculoskeletal Conditions","Evaluation of Regenerative Medicine Outcomes With Umbilical Allograft for Musculoskeletal Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n\n4\\) Competent to understand the study protocol and provide voluntary informed consent.\n\nExclusion Criteria:\n\n1. Active Infection\n2. Pregnancy, Lactating\n3. Clotting disorder",true,"18 Years",{"count":59,"type":19},200,[61],"NA","The aim of the study is to determine the efficacy of an Amniotic Fluid Tissue Product for pain relief and functional improvements for all types of musculoskeletal conditions. The study is prospective, with outcome measures being obtained at numerous time points after the regenerative procedure.",[64,65,66,67,68,69,70,71],"Osteoarthritis","Tendinitis","Sports Injury","Degenerative Disc Disease","Degenerative Arthritis","Ligament Injury","Neuropathy","Pelvic Pain",[73,74,75,34,76,77],"regenerative medicine","arthritis","amniotic","growth factor","cartilage","NOT_YET_RECRUITING","2021-09-10",{"date":81,"type":40},"2021-09-17",{"date":83,"type":19},"2022-01-01",{"date":85,"type":19},"2030-01-01",{"name":46,"class":47},1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":56,"sex":15,"minAge":57,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":20,"phases":97,"briefSummary":98,"conditions":99,"keywords":117,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",{"count":96,"type":19},5000,[22],"To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116],"Orthopedic Disorder","Neurologic Disorder","Urologic Diseases","Erectile Dysfunction","Autoimmune Diseases","Renal Failure","Renal Insufficiency","Kidney Diseases","Cardiac Event","Cardiomyopathies","CHF","Pulmonary Disease","COPD","Alzheimer Disease","Stroke","Neuropathy;Peripheral","Arthritis",[118,119,120,121,73,122,123,124],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","r3 stem cell","perinatal tissue","placenta stem cell","2019-08-20",{"date":127,"type":40},"2019-08-22",{"date":129,"type":19},"2019-09-01",{"date":131,"type":19},"2029-03-20",{"name":46,"class":47},""]